

Erratum to: Prolonged thrombocytopenia after living donor liver transplantation is a strong prognostic predictor irrespective of history of splenectomy: the significance of ADAMTS13 and graft function

Yu Nobuoka¹ · Hideo Wada² · Shugo Mizuno¹ · Masashi Kishiwada¹ · Masanobu Usui¹ · Hiroyuki Sakurai¹ · Masami Tabata¹ · Toshihiko Kobayashi³ · Tsutomu Nobori² · Shinji Uemoto⁴ · Shuji Isaji¹

Published online: 21 April 2016
© The Japanese Society of Hematology 2016

Erratum to: Int J Hematol (2014) 99:418–428 DOI 10.1007/s12185-014-1543-9

The author would like to correct the errors in the publication of the original article. The corrected details are given below for your reading.

The original article was published with the incorrect title. The correct title should read: “Prolonged thrombocytopenia after living donor liver transplantation is a strong prognostic predictor irrespective of splenectomy: the significance of ADAMTS13 and graft function”.

Secondly, the last two sentences beneath the heading “Abstract” should read as “Irrespective of splenectomy, platelet counts and ADAMTS13 activity in the LP group remained low until POD28, while VWF/ADAMTS13 ratio significantly increased until POD28. These results suggest that prolonged thrombocytopenia after LDLT was associated with not only a decrease in ADAMTS13 due to sinusoidal endothelial cell injury, but also low TPO




Fig. 1 Comparison of postoperative platelet counts between LDLT and other operative procedures with or without splenectomy (with standard error bars)

production due to hepatocyte dysfunction, irrespective of splenectomy.”

Errors have subsequently been identified in the original publication, and the following corrections should be noted:

1. The revised Figs. 1 and 5 and Tables 1, 2, 3 and 4 were replaced with this erratum.
2. References [18] and [27] should be replaced as below.

18. Takei Y, Marzi I, Gao WS, Gores GJ, Lemasters JJ, Thurman RG. Leukocyte adhesion and cell death following orthotopic liver transplantation in the rat. *Transplantation*. 1991;51(5):959–65.

27. Cywes R, Mullen JB, Stratis MA, Greig PD, Levy GA, Harvey PR, Strasberg SM. Prediction of the outcome of transplantation in man by platelet adherence in donor liver allografts. Evidence of the importance of prepreservation injury. *Transplantation*. 1993;56(2):316–23.

The online version of the original article can be found under doi:10.1007/s12185-014-1543-9.

✉ Hideo Wada
wadahide@clin.medic.mie-u.ac.jp

- ¹ Department of Hepatobiliary-Pancreatic and Transplant Surgery, Mie University Graduate School of Medicine, Tsu, Mie, Japan
- ² Department of Molecular and Laboratory Medicine, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie 514-0001, Japan
- ³ Department of Hematology, Mie University Graduate School of Medicine, Tsu, Mie, Japan
- ⁴ Hepatobiliary Pancreatic and Transplantation Surgery, Kyoto University Graduate School, Kyoto, Japan




Fig. 5 Correlation between PLT and TB/PT-INR, ADAMTS13 and TB/PT-INR, and TPO levels and TB/PT-INR on POD14. The *open circles* designate patients who died within 6 months of LT

Table 1 Background of the 100 adult LDLT recipients ($n = 100$)

| | |
|---------------------------|----------------------------------|
| Age (year old) | 53.7 (20–70) |
| Gender (male/female) | 61/39 |
| Etiology of liver disease | |
| Liver cirrhosis (HCC) | 68 (39) |
| PBC | 14 |
| PSC | 2 |
| Fulminant hepatitis | 11 |
| Others | 5 |
| C-P score | 9.6 (5–15) |
| MELD score | 17.9 (6–45) |
| Donor age (year old) | 38.0 (18–65) |
| Graft (right/left/post) | 64/34/2 |
| GRWR (%) | 0.969 (0.441–1.571) |
| WIT (min) | 48.7 (21–113) |
| CIT (min) | 108.9 (10–424) |
| Splenectomy | 29 (29 %) |
| Blood loss (ml) | 11115 ^a (1426–74,480) |
| Transfusion | |
| RBC (unit) | 41 ^a (4–213) |
| Platelet (unit) | 40 ^a (0–120) |
| FFP (unit) | 40 ^a (0–152) |

HCC hepatocellular carcinoma, *PBC* primary biliary cirrhosis, *PSC* primary sclerosing cholangitis, *C-P* Child-Pugh, *MELD* modified end-stage liver disease, *GRWR* graft to recipient weight ratio, *WIT* warm ischemia time, *CIT* cold ischemia time, *RBC* red blood cells, *FFP* fresh frozen plasma

^a Median

Table 2 Postoperative complications in LP and HP groups

| | LP group ($n = 36$) | HP group ($n = 62$) | <i>P</i> value |
|-----------------|--------------------------|--------------------------|----------------|
| Complication | 15 (41.7 %) | 12 (19.4 %) | 0.02 |
| Pneumonia | 5 | 3 | 0.12 |
| Sepsis | 4 | 5 | 0.33 |
| Biliary leakage | 0 | 5 | 0.10 |
| ARF | 7 | 2 | 0.01 |
| HAT | 4 | 2 | 0.13 |

Bold values indicate statistically significant differences

ARF acute renal failure (all recipients underwent renal replacement therapy), *HAT* hepatic artery thrombosis

Table 3 Patient characteristics (HP and LP group)

| | All (<i>n</i> = 65) | HP group (<i>n</i> = 42) | LP group (<i>n</i> = 23) | <i>P</i> |
|------------------------------|----------------------|---------------------------|---------------------------|----------|
| Preoperative factor | | Mean ± S.D. | | |
| Age (years) | 53.09 ± 10.44 | 52.36 ± 11.71 | 54.39 ± 7.98 | 0.461 |
| Gender (male) | 39 (60.0 %) | 27 (64.3 %) | 12 (52.2 %) | 0.198 |
| C-P score | <i>9.65 ± 2.58</i> | <i>8.69 ± 2.32</i> | <i>11.17 ± 2.04</i> | <0.001 |
| MELD score | <i>18.30 ± 9.57</i> | <i>15.60 ± 7.86</i> | <i>22.22 ± 10.00</i> | 0.009 |
| GRWR (%) | 1.02 ± 0.19 | 1.04 ± 0.19 | 0.97 ± 0.18 | 0.168 |
| Platelet | 75.47 ± 61.13 | 82.69 ± 58.84 | 64.17 ± 65.34 | 0.248 |
| AT (%) | <i>51.33 ± 25.19</i> | <i>58.17 ± 25.58</i> | <i>39.22 ± 20.41</i> | 0.003 |
| ADAMTS13 (%) | 69.09 ± 36.96 | 75.84 ± 37.47 | 59.24 ± 32.94 | 0.080 |
| vWF (%) | 285.35 ± 156.22 | 275.26 ± 150.77 | 309.30 ± 167.97 | 0.406 |
| vWF/ADAMTS13 | 6.77 ± 8.57 | 5.56 ± 5.001 | 8.72 ± 12.73 | 0.158 |
| Intraoperative factor | | | | |
| Splenectomy | 1 (21.4 %) | 9/42 (21.4 %) | 5/23 (21.7 %) | 0.606 |
| CIT (min) | 110.34 ± 73.82 | 106.56 ± 54.88 | 120.17 ± 100.09 | 0.551 |
| WIT (min) | 46.78 ± 16.31 | 48.76 ± 18.09 | 43.13 ± 12.53 | 0.191 |
| Blood loss (ml) | 16370 ± 15363 | 17122 ± 17822 | 15379 ± 9987 | 0.615 |
| Transfusion | | | | |
| RBC (unit) | 43.02 ± 40.44 | 43.26 ± 45.42 | 43.30 ± 31.20 | 0.997 |
| FFP (unit) | 37.33 ± 34.58 | 38.33 ± 36.94 | 36.26 ± 31.20 | 0.820 |
| Platelet (unit) | 33.56 ± 27.04 | 32.26 ± 29.64 | 34.78 ± 22.08 | 0.722 |
| PVP (mmHg) | 18.92 ± 5.05 | 18.62 ± 4.72 | 19.57 ± 5.70 | 0.481 |
| Postoperative factor (POD14) | | | | |
| TB (mg/dl) | <i>5.63 ± 6.93</i> | <i>3.38 ± 4.92</i> | <i>9.65 ± 8.18</i> | 0.002 |
| PT-INR | <i>1.18 ± 0.27</i> | <i>1.09 ± 0.15</i> | <i>1.35 ± 0.36</i> | 0.003 |
| CRP | 4.40 ± 4.65 | 3.95 ± 4.38 | 5.61 ± 5.21 | 0.192 |
| AT (%) | <i>81.49 ± 22.11</i> | <i>89.54 ± 14.48</i> | <i>67.49 ± 26.13</i> | 0.001 |
| ADAMTS13 (%) | <i>33.34 ± 21.03</i> | <i>39.94 ± 21.22</i> | <i>21.73 ± 15.09</i> | 0.001 |
| vWF (%) | 285.35 ± 156.22 | 343.40 ± 100.96 | 336.03 ± 125.66 | 0.802 |
| vWF/ADAMTS13 | 23.31 ± 38.47 | 15.99 ± 21.50 | 35.87 ± 55.44 | 0.129 |

Italic values indicate statistically significant differences

C-P Child-Pugh score, *MELD* modified end-stage liver disease, *GRWR* graft to recipient weight ratio, *AT* antithrombin, *ADAMTS13* a disintegrin and metalloproteinase with a thrombospondin type 1 motifs 13, *vWF* von Willebrand Factor, *CIT* cold ischemia time, *WIT* warm ischemia time, *RBC* red blood cell, *FFP* fresh-frozen plasma, *PVP* portal venous pressure, *TB* total bilirubin, *PT-INR* prothrombin time international normalized ratio, *CRP* C-reactive protein

Table 4 Risk factors for postoperative thrombocytopenia on POD14

| | Univariate analysis (<i>n</i> = 65) | | Multivariate analysis | |
|------------------------------|--------------------------------------|------------------|------------------------|--------------|
| | Correlation coefficients | <i>P</i> | Regression coefficient | <i>P</i> |
| Preoperative factor | | | | |
| C-P score | <i>-0.445</i> | <i><0.001</i> | -0.088 | 0.632 |
| MELD score | <i>-0.309</i> | <i>0.012</i> | 0.053 | 0.296 |
| Platelet | 0.362 | <i>0.003</i> | 0.032 | 0.829 |
| AT (%) | <i>0.379</i> | <i>0.003</i> | <i>0.417</i> | <i>0.002</i> |
| Postoperative factor (POD14) | | | | |
| TB (mg/dl) | <i>-0.430</i> | <i><0.001</i> | -0.171 | 0.244 |
| PT-INR | <i>-0.324</i> | <i>0.010</i> | -0.122 | 0.352 |
| AT (%) | <i>0.431</i> | <i><0.001</i> | 0.212 | 0.137 |
| ADAMTS13 (%) | <i>0.416</i> | <i>0.001</i> | <i>0.331</i> | <i>0.011</i> |

Italic values indicate statistically significant differences

C-P Child-Pugh score, *MELD* modified end-stage liver disease, *AT* antithrombin, *TB* total bilirubin, *PT-INR* prothrombin time international normalized ratio, *ADAMTS13* a disintegrin and metalloproteinase with a thrombospondin type 1 motifs 13